Milan, March 29, 2024 – Neopharmed Gentili S.p.A., a joint stock company (società per azioni) incorporated under the laws of Italy (the “Issuer” or “Neopharmed”), has successfully completed today the placement on the high-yield bond market (the “Offering”) of €750.0 million of Senior Secured Notes, consisting of €350.0 million in aggregate principal amount of Senior Secured Fixed Rate Notes due 2030 and €400.0 million in aggregate principal amount of Senior Secured Floating Rate Notes due 2030 (collectively, the “Notes”).
Read moreEric Falcand is the new CEO of Neopharmed Gentili
Milan, October, 31st 2023 – Eric Falcand is the new CEO of Neopharmed Gentili, a pharmaceutical company specialised in the commercialisation of high-value therapeutic solutions, historically rooted in Italy and rapidly expanding beyond national borders, controlled by private equity firms Ardian and NB Renaissance in partnership with the Del Bono family. Falcand succeeds Alessandro Del Bono, who will continue as Executive Chairman.
Read moreMilan, 9 March 2023– The pharmaceutical company Neopharmed Gentili participates with a donation of 50,000 euros in the fundraising launched by the Italian Red Cross (CRI) in favor of communities affected by the violent earthquake in Turkey and Syria. The funds will be used to support the activities of Volunteers and Red Cross operators engaged in the front line of operations to support populations who are experiencing a situation of serious difficulty.
Read moreMilan, 27 July 2022 – Neopharmed Gentili, an Italian pharmaceutical company specialized in the marketing of solutions with high therapeutic value, controlled by Ardian in partnership with the Del Bono family, has acquired 100% of Valeas, a historic Italian company with widely-recognized leadership in pediatric, broncho-pneumological, rhinological and neuropsychiatric (CNS) fields.
Read moreNeopharmed Gentili acquires Lormetazepam product
Milan, 1st March, 2022- Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian in partnership with the Del Bono family, which has historic roots in its territory and is pursuing international growth, announced that it has entered into an agreement with Bayer for the acquisition of the rights in Italy and Japan to the historical brands Minias® and Noctamid® (Italy) and Evamyl® (Japan). Lormetazepam products are indicated in the short-term treatment of insomnia, in particular anxiety-induced insomnia.
Read moreNeopharmed Gentili acquires Lormetazepam product portfolio to strengthen its neurology division
Milan, 1st March, 2022 – Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian in partnership with the Del Bono family, which has historic roots in its territory and is pursuing international growth, announced that it has entered into an agreement with Bayer for the acquisition of the rights in Italy and Japan to the historical brands Minias® and Noctamid® (Italy) and Evamyl® (Japan). Lormetazepam products are indicated in the short-term treatment of insomnia, in particular anxiety-induced insomnia.
Read moreANNUAL REPORT SOCIAL 2020 NEOPHARMED GENTILI
SOCIAL MEDIA REPORT 2020 – TWITTER – INSTAGRAM – LINKEDIN
Press Release
PDF download
